Research output: Contribution to journal › Article › peer-review
Radiobiological response of U251MG, CHO-K1 and V79 cell lines to accelerator-based boron neutron capture therapy. / Sato, Eisuke; Zaboronok, Alexander; Yamamoto, Tetsuya et al.
In: Journal of Radiation Research, Vol. 59, No. 2, 01.03.2018, p. 101-107.Research output: Contribution to journal › Article › peer-review
}
TY - JOUR
T1 - Radiobiological response of U251MG, CHO-K1 and V79 cell lines to accelerator-based boron neutron capture therapy
AU - Sato, Eisuke
AU - Zaboronok, Alexander
AU - Yamamoto, Tetsuya
AU - Nakai, Kei
AU - Taskaev, Sergey
AU - Volkova, Olga
AU - Mechetina, Ludmila
AU - Taranin, Alexander
AU - Kanygin, Vladimir
AU - Isobe, Tomonori
AU - Mathis, Bryan J.
AU - Matsumura, Akira
N1 - Publisher Copyright: © The Author(s) 2017.
PY - 2018/3/1
Y1 - 2018/3/1
N2 - In the current article, we provide in vitro efficacy evaluation of a unique accelerator-based neutron source, constructed at the Budker Institute of Nuclear Physics (Novosibirsk, Russian Federation), for boron neutron capture therapy (BNCT), which is particularly effective in the case of invasive cancers. U251MG, CHO-K1 and V79 cells were incubated and irradiated in various concentrations of boric acid with epithermal neutrons for 2–3 h in a plexiglass phantom, using 2.0 MeV proton energy and 1.5–3.0 mA proton current, resulting in a neutron fluence of 2.16 × 1012 cm−2. The survival curves of cells loaded with boron were normalized to those irradiated without boron (to exclude the influence of the fast neutron and gamma dose components) and fit to the linear–quadratic (LQ) model. Colony formation assays showed the following cell survival rates (means ± SDs): CHO-K1: 0.348 ± 0.069 (10 ppm), 0.058 ± 0.017 (20 ppm), 0.018 ± 0.005 (40 ppm); V79: 0.476 ± 0.160 (10 ppm), 0.346 ± 0.053 (20 ppm), 0.078 ± 0.015 (40 ppm); and U251MG: 0.311 ± 0.061 (10 ppm), 0.131 ± 0.022 (20 ppm), 0.020 ± 0.010 (40 ppm). The difference between treated cells and controls was significant in all cases (P < 0.01) and confirmed that the neutron source and irradiation regimen were sufficient for control over cell colony formation. We believe our study will serve as a model for ongoing in vitro experiments on neutron capture therapy to advance in this area for further development of accelerator-based BNCT into the clinical phase.
AB - In the current article, we provide in vitro efficacy evaluation of a unique accelerator-based neutron source, constructed at the Budker Institute of Nuclear Physics (Novosibirsk, Russian Federation), for boron neutron capture therapy (BNCT), which is particularly effective in the case of invasive cancers. U251MG, CHO-K1 and V79 cells were incubated and irradiated in various concentrations of boric acid with epithermal neutrons for 2–3 h in a plexiglass phantom, using 2.0 MeV proton energy and 1.5–3.0 mA proton current, resulting in a neutron fluence of 2.16 × 1012 cm−2. The survival curves of cells loaded with boron were normalized to those irradiated without boron (to exclude the influence of the fast neutron and gamma dose components) and fit to the linear–quadratic (LQ) model. Colony formation assays showed the following cell survival rates (means ± SDs): CHO-K1: 0.348 ± 0.069 (10 ppm), 0.058 ± 0.017 (20 ppm), 0.018 ± 0.005 (40 ppm); V79: 0.476 ± 0.160 (10 ppm), 0.346 ± 0.053 (20 ppm), 0.078 ± 0.015 (40 ppm); and U251MG: 0.311 ± 0.061 (10 ppm), 0.131 ± 0.022 (20 ppm), 0.020 ± 0.010 (40 ppm). The difference between treated cells and controls was significant in all cases (P < 0.01) and confirmed that the neutron source and irradiation regimen were sufficient for control over cell colony formation. We believe our study will serve as a model for ongoing in vitro experiments on neutron capture therapy to advance in this area for further development of accelerator-based BNCT into the clinical phase.
KW - Accelerator-based neutron source
KW - Boric acid
KW - Boron neutron capture therapy
KW - In vitro efficacy evaluation
KW - Lithium target
KW - boric acid
KW - TARGET
KW - TSUKUBA
KW - boron neutron capture therapy
KW - BNCT
KW - lithium target
KW - NECK-CANCER
KW - accelerator-based neutron source
KW - NANOPARTICLES
KW - IN-VITRO
KW - GLIOBLASTOMA
KW - TRANSPORT
KW - RECURRENT HEAD
KW - in vitro efficacy evaluation
UR - http://www.scopus.com/inward/record.url?scp=85052016832&partnerID=8YFLogxK
U2 - 10.1093/jrr/rrx071
DO - 10.1093/jrr/rrx071
M3 - Article
C2 - 29281044
AN - SCOPUS:85052016832
VL - 59
SP - 101
EP - 107
JO - Journal of Radiation Research
JF - Journal of Radiation Research
SN - 0449-3060
IS - 2
ER -
ID: 16104983